These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 9354422

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM.
    Cancer Res; 1999 May 01; 59(9):2203-9. PubMed ID: 10232609
    [Abstract] [Full Text] [Related]

  • 4. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW.
    J Urol; 2005 May 01; 173(5):1778-83. PubMed ID: 15821586
    [Abstract] [Full Text] [Related]

  • 5. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
    Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS.
    Cancer Res; 2000 Aug 01; 60(15):4093-7. PubMed ID: 10945615
    [Abstract] [Full Text] [Related]

  • 6. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM.
    Cancer Res; 1997 Aug 15; 57(16):3325-30. PubMed ID: 9269988
    [Abstract] [Full Text] [Related]

  • 7. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies.
    Martiniello-Wilks R, Dane A, Mortensen E, Jeyakumar G, Wang XY, Russell PJ.
    Anticancer Res; 2003 Aug 15; 23(3B):2633-42. PubMed ID: 12894551
    [Abstract] [Full Text] [Related]

  • 8. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL, Xie Z, Yu J, Martin WD, Datta MW, Wu GJ, Chung LW.
    Prostate; 2007 May 15; 67(7):685-91. PubMed ID: 17342752
    [Abstract] [Full Text] [Related]

  • 9. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Johnson MA, Iversen P, Schwier P, Corn AL, Sandusky G, Graff J, Neubauer BL.
    Prostate; 2005 Mar 01; 62(4):322-38. PubMed ID: 15389779
    [Abstract] [Full Text] [Related]

  • 10. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.
    Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A.
    Clin Cancer Res; 2008 May 15; 14(10):2936-43. PubMed ID: 18483360
    [Abstract] [Full Text] [Related]

  • 11. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice.
    Bono AV, Montironi R, Pannellini T, Sasso F, Mirone V, Musiani P, Iezzi M.
    Prostate Cancer Prostatic Dis; 2008 May 15; 11(4):377-83. PubMed ID: 18379588
    [Abstract] [Full Text] [Related]

  • 12. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Yeh IT, Reddick RL, Kumar AP.
    Prostate; 2009 May 15; 69(7):755-60. PubMed ID: 19170049
    [Abstract] [Full Text] [Related]

  • 13. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
    Ghosh R, Graham H, Rivas P, Tan XJ, Crosby K, Bhaskaran S, Schoolfield J, Banu J, Fernandes G, Yeh IT, Kumar AP.
    Anticancer Res; 2010 Mar 15; 30(3):857-65. PubMed ID: 20393007
    [Abstract] [Full Text] [Related]

  • 14. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
    Jeet V, Ow K, Doherty E, Curley B, Russell PJ, Khatri A.
    Prostate; 2008 Apr 01; 68(5):548-62. PubMed ID: 18247402
    [Abstract] [Full Text] [Related]

  • 15. Metastatic prostate cancer in a transgenic mouse.
    Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM.
    Cancer Res; 1996 Sep 15; 56(18):4096-102. PubMed ID: 8797572
    [Abstract] [Full Text] [Related]

  • 16. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
    Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A.
    Cancer Res; 2001 Sep 15; 61(18):6777-82. PubMed ID: 11559550
    [Abstract] [Full Text] [Related]

  • 17. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
    Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, Basilico C, Ittmann M.
    Cancer Res; 2003 Sep 15; 63(18):5754-60. PubMed ID: 14522896
    [Abstract] [Full Text] [Related]

  • 18. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
    Bethel CR, Bieberich CJ.
    Prostate; 2007 Dec 01; 67(16):1740-50. PubMed ID: 17929276
    [Abstract] [Full Text] [Related]

  • 19. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
    Suttie AW, Dinse GE, Nyska A, Moser GJ, Goldsworthy TL, Maronpot RR.
    Toxicol Pathol; 2005 Dec 01; 33(3):386-97. PubMed ID: 15805078
    [Abstract] [Full Text] [Related]

  • 20. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD, Zakrajsek BA, Hill RE, Liu Q, Reeves JJ, Axford PD, Singer MJ, Reed MW.
    Prostate; 2003 Jun 01; 55(4):308-16. PubMed ID: 12712410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.